NCT02208934

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Academic / Other
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers

Conditions

• Huntington's Disease

Interventions

Type	Name	Description
DRUG	PBF-999	5, 10, 20 and 40 mg of PBF-999
DRUG	Placebo	Placebo for all dosis of PBF-999

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2014-08-05
• Last updated: 2016-03-08

Locations

2 sites across 1 country: Spain